July 30, 2024
Artificial intelligence (AI) is revolutionizing clinical trials, offering greater efficiency and precision. At the Alzheimer’s Association International Conference (AAIC) 2024, Unlearn AI, in collaboration with Johnson & Johnson Innovative Medicine and AbbVie, demonstrated how AI-generated digital twins are transforming randomized clinical trials (RCTs). This technology reduces control arm sizes and increases statistical power, ultimately making drug development faster and more cost-effective.
1. AI-Powered Digital Twins: A Paradigm Shift in Clinical Trials
Traditional clinical trials require large control groups, limiting patient access to new treatments. However, Unlearn’s Digital Twin Generators create AI-powered forecasts of patient outcomes, reducing control arm sizes and significantly boosting trial efficiency.
2. Collaboration with Johnson & Johnson Innovative Medicine
In a groundbreaking collaboration, Unlearn AI applied its Digital Twin Generator to three Phase III Alzheimer’s Disease trials. Key outcomes include:
- 33% reduction in control arm size when assessing ADAS-Cog11 at 18 months.
- 19% reduction in control arm size for CDR-SB at 12 months.
- 10% power gain (from 80% to 90%) with ADAS-Cog11.
This innovative approach accelerates trials, reduces costs, and improves patient access to new treatments.
3. Collaboration with AbbVie
In a Phase II Alzheimer’s Disease study, Unlearn’s AI technology resulted in:
- 10-15% reduction in total sample size.
- 7% increase in trial power (from 80% to 87%) with CDR-SB.
These advancements reduce patient requirements while maintaining statistical reliability, streamlining the drug approval process.
4. The Future of AI in Clinical Development
AI-powered digital twins have the potential to revolutionize clinical trials by addressing key challenges:
- Faster drug development timelines.
- Lower trial costs and improved efficiency.
- Increased patient access to experimental treatments.
- Higher statistical confidence in trial outcomes.
AI at Johnson & Johnson: Advancing Precision Medicine
With industry leaders like Johnson & Johnson, AbbVie, and Unlearn AI, the future of drug development is evolving into a more efficient, data-driven, and patient-centric process. AI continues to fuel personalized medicine and therapeutic advancements, setting the stage for transformative breakthroughs.
About Unlearn AI
Unlearn AI is pioneering the future of clinical research through AI-generated digital twins. Their technology helps pharmaceutical and biotech companies streamline clinical trials and enhance decision-making. Unlearn’s platform is FDA-compliant and EMA-qualified for Phase 3 clinical trials, providing innovative solutions for the pharmaceutical industry.
By
